CrossBoss First Shows Promise for Antegrade CTO PCI

CrossBoss First Shows Promise for Antegrade CTO PCI 647 377 C-Suite Network

The small study compared use of a dedicated catheter for antegrade CTO crossing with a standard wire escalation strategy.

CrossBoss First Shows Promise for Antegrade CTO PCI

DENVER, CO—Upfront use of a dedicated catheter for antegrade crossing of coronary chronic total occlusions (CTOs) results in similar crossing time, success rates, complications, equipment utilization, and cost compared with a primary wire-escalation strategy, according to results of the CrossBoss First study.

Among 246 patients referred for antegrade CTO PCI, the primary efficacy endpoint of crossing time was similar with both crossing strategies, Emmanouil S. Brilakis, MD, PhD (Minneapolis Heart Institute, Minneapolis, MN), said during the First Report Investigation session. The primary safety endpoint of procedural MACE, including death, MI, urgent repeat TVR, tamponade requiring pericardiocentesis or surgery, and stroke, was also comparable, at 3.28% with the CrossBoss CTO crossing catheter (Boston Scientific) compared with 4.03% with wire escalation (P = 0.1).

The randomized controlled CrossBoss First study, published simultaneously yesterday in JACC: Cardiovascular Interventions, was conducted at 11 US centers, with procedures performed by experienced operators. Brilakis acknowledged there is a learning curve for using CTO crossing devices and techniques, but said high success rates can be achieved.

Eligible patients were…